Accepted Manuscript

Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies

Julia D. Ransohoff, BA, Bernice Y. Kwong, MD

PII: S2152-2650(17)30797-8

DOI: 10.1016/j.clml.2017.07.005

Reference: CLML 976

To appear in: Clinical Lymphoma, Myeloma and Leukemia

Received Date: 19 May 2017

Revised Date: 2152-2650 2152-2650

Accepted Date: 10 July 2017

Please cite this article as: Ransohoff JD, Kwong BY, Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies, *Clinical Lymphoma, Myeloma and Leukemia* (2017), doi: 10.1016/j.clml.2017.07.005.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies Julia D. Ransohoff, BA^1 , Bernice Y. Kwong, $MD^{1\star}$

Stanford University School of Medicine, Department of Dermatology, Stanford CA 94305
Corresponding author: Bernice Y. Kwong, bernicek@stanford.edu

Tables and Figures: 6

Word count (main text): 7,701

Conflicts of interest: None declared.

Funding sources: None.

Download English Version:

https://daneshyari.com/en/article/8615815

Download Persian Version:

https://daneshyari.com/article/8615815

<u>Daneshyari.com</u>